CV: HF, MYOCARDIAL INFARCTION, STROKE, edema, hypertension, vasculitis.
Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), EXFOLIATIVE DERMATITIS, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, ↑ sweating, photosensitivity, pruritus, rash.
EENT: abnormal vision, tinnitus.
F and E: hyperkalemia.
GI: GI BLEEDING, abdominal pain, diarrhea, dyspepsia, ↑ liver enzymes, anorexia, cholestatic jaundice, constipation, dry mouth, duodenal ulcer, flatulence, gastritis, ↑ appetite, nausea, stomatitis, vomiting.
GU: albuminuria, azotemia, interstitial nephritis.
Hemat: prolonged bleeding time.
Metab: weight gain.
Neuro: paresthesia, tremor, agitation, anxiety, confusion, depression, dizziness, drowsiness, fatigue, headache, insomnia, malaise, weakness.
Resp: dyspnea, hypersensitivity pneumonitis.
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA).
Osteoarthritis or Rheumatoid Arthritis
- PO (Adults): 1200 mg once daily; onset may be more rapid with an initial 1800-mg dose. Patients with low body weight, mild disease, or renal impairment may be started at 600 mg/day (not to exceed 1800 mg/day or 26 mg/kg/day). Daily doses >1200 mg should be given in 2–3 divided doses. Consideration should be given to ↓ dose to lowest effective amount.
Juvenile Rheumatoid Arthritis
- PO (Children 6–16 yr):
55 kg — 1200 mg once daily; 32–54 kg — 900 mg once daily; 22–31 kg — 600 mg once daily.
Therapeutic Classification: antirheumatics, nonopioid analgesics
Pharmacologic Classification: nonsteroidal anti-inflammatory drugs (NSAIDs)
Absorption: Well absorbed following oral administration (80%); 35% is rapidly converted to an active metabolite.
Distribution: Unknown.
Protein Binding: 99.9%.
Metabolism/Excretion: The active metabolite is metabolized by the liver to inactive compounds.
Half-life: 42–50 hr.
